Literature DB >> 29914912

Fecal microbiota transplantation for recurrent Clostridium difficile infection.

Susy S Hota1, Susan M Poutanen2.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29914912      PMCID: PMC6008194          DOI: 10.1503/cmaj.171454

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

Review 1.  The Human Intestinal Microbiome in Health and Disease.

Authors:  Susan V Lynch; Oluf Pedersen
Journal:  N Engl J Med       Date:  2016-12-15       Impact factor: 91.245

Review 2.  Faecal microbiota transplantation for <em>Clostridium difficile</em>-associated diarrhoea: a systematic review of randomised controlled trials.

Authors:  Paul Moayyedi; Yuhong Yuan; Harith Baharith; Alexander C Ford
Journal:  Med J Aust       Date:  2017-08-21       Impact factor: 7.738

3.  Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.

Authors:  Susy S Hota; Valerie Sales; George Tomlinson; Mary Jane Salpeter; Allison McGeer; Bryan Coburn; David S Guttman; Donald E Low; Susan M Poutanen
Journal:  Clin Infect Dis       Date:  2016-11-09       Impact factor: 9.079

  3 in total
  2 in total

Review 1.  Role of Surgery in Clostridium difficile Infection.

Authors:  Aela Vely; Paula Ferrada
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

2.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.